Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.

The success of enzymatic replacement in Gaucher disease has stimulated development of targeted protein replacement for other lysosomal disorders, including Anderson-Fabry disease, which causes fatal cardiac, cerebrovascular and renal injury: deficiency of lysosomal α-Galactosidase A induces accumulation of glycosphingolipids. Endothelial cell storage was the primary endpoint in a clinical trial that led to market authorization. Two α-Galactosidase A preparations are licensed worldwide, but fatal outcomes persist, with storage remaining in many tissues. We compare mechanisms of uptake of α -Galactosidase A into cells relevant to Fabry disease, in order to investigate if the enzyme is targeted to the lysosomes in a mannose-6-phosphate receptor dependent fashion, as generally believed. α -Galactosidase A uptake was examined in fibroblasts, four different endothelial cell models, and hepatic cells in vitro. Uptake of europium-labeled human α -Galactosidase A was measured by time-resolved fluorescence. Ligand-specific uptake was quantified in inhibitor studies. Targeting to the lysosome was determined by precipitation and by confocal microscopy. The quantity and location of cation-independent mannose-6-phosphate receptors in the different cell models were investigated using confocal microscopy. Uptake and delivery of α -Galactosidase A to lysosomes in fibroblasts is mediated by the canonical mannose-6-phosphate receptor pathway, but in endothelial cells in vitro this mechanism does not operate. Moreover, this observation is supported by a striking paucity of expression of cation independent mannose-6-phosphate receptors on the plasma membrane of the four endothelial cell models and by little delivery of enzyme to lysosomes, when compared with fibroblasts. If these observations are confirmed in vivo, alternative mechanisms will be needed to explain the ready clearance of storage from endothelial cells in patients undergoing enzyme replacement therapy.

Solvent effects on the conformational distribution and optical rotation of gamma-methyl paraconic acids and esters.

A computational investigation of the optical rotatory power of cis and trans 2-methyl-5-oxo-tetrahydro-3-furancarboxylic acids and the corresponding methyl and ethyl esters is presented. Solvent effects on both the conformational space and the rotatory power are analyzed by comparing results obtained in vacuo with those computed--using the Polarizable Continuum Model--in methanol. A comparison with experimental observations for the optical rotatory power of the title compounds in methanol is also carried out, in a few cases also for several wavelengths. Agreement between theory and experiment is in all cases excellent, in particular when solvent effects are included both in the geometry optimization and in the calculation of the OR, thus confirming the validity of the computational procedure adopted, even for this challenging family of floppy molecules.

Optical rotation calculation of a highly flexible molecule: the case of paraconic acid.

The absolute configuration of (S)-(-)-paraconic acid is correctly assigned on the basis of ab initio calculations of the specific optical rotation (OR) at the sodium D line, carried out both in vacuum and in methanol. Density functional theory (DFT) and Møller-Plesset second-order perturbation theory (MP2) are used to determine the most stable conformational structures, whose OR values are then calculated using DFT linear response theory and London atomic orbitals. The total OR is obtained by averaging these values using the population fractions determined from Boltzmann's statistics. The total OR of the MP2 structures has the correct sign both in vacuum and in solution, whereas only the solvent-relaxed DFT structures correctly reproduce the experimental sign. The strong solvent effect on the total OR is shown to arise primarily due to the variations in the relative energies of the various conformations.